Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 94

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 94
---
oma.

The results of Phase I and Phase II clinical trials will determine further drug development and Shuttle will seek to establish collaborative partnerships with other pharmaceutical companies to complete pre-clinical and clinical development, drug manufacturing and marketing of our product candidates. In the event we are unsuccessful in completing our clinical trials at any stage, or in the event we obtain negative results, we will likely be unable to raise additional funding related to our HDAC studies or will have to change direction of our research efforts regarding the HDAC inhibitor platform of candidate molecules.

Our Manufacturing Strategy

We have no manufacturing facilities that are owned or operated by us. We have performed laboratory scale synthesis and testing in our research laboratories in Gaithersburg, Maryland. GMP synthesis of API, drug formulation and human dosage preparation will be performed under contracts with third-party manufacturers.

| 61 |

Strategic Agreements

We have developed important strategic agreements with academic institutions for access to resources such as intellectual property, core facilities and contracting relationships. In addition, we have established an agreement with Propagenix for intellectual property in-licensing. Our current and ongoing relationships include:

| ● | Georgetown 
 University |

| ○ | Sub-contractor                                                                                                                         
 for the SBIR supported African American prostate cancer patient health disparities project (completed). The conditional reprogramming  
 of cells (CRC) technology was invented at Georgetown University and Georgetown University owns the intellectual property. Propagenix   
 holds the license for the intellectual property for the CRC technology from Georgetown University. The intellectual property for       
 cells derived from African American patients under the Georgetown University subcontract belong to Shuttle Pharmaceuticals, Inc.       
 based on our sub-licensing agreement with Propagenix.                                                                                  |
| ○ | Sub-contractor                                                                                                                         
 for the SBIR supported metabolomic predictive biomarker project (completed). The metabolomic biomarker intellectual property belongs   
 to Georgetown University and Shuttle Pharma holds an exclusive option to license the intellectual property.                            |
| ○ | Exclusive                                                                                                                              
 licensing agreement with Georgetown University pursuant to which Georgetown University agreed to license the intellectual property     
 known as “Predictive Biomarkers for Adverse Effects of Radiation Therapy” (U.S. Patent Application No. 17/476,184, filed               
 on September 15, 2021) (the “Patent Rights”), which was developed by Dr. Anatoly Dritschilo, the Company’s Chief                       
 Executive Officer, Dr. Scott Grindrod, the Company’s Principal Scientist, and Drs. Amrita Cheema and Yaoxiang Li